Claims for Patent: 9,951,368

Summary for Patent: 9,951,368

Title:	Methods of DNA constructs for high yield production of polypeptides
Abstract:	The invention provides an inclusion body fusion partner to increase peptide and polypeptide production in a cell.
Inventor(s):	Williams; James A. (Lincoln, NE), Luan; Peng (Fishers, IN), Xia; Yuannan (Lincoln, NE), Harley; Scott (Pensacola, FL)
Assignee:	Medtronic, Inc. (Minneapolis, MN)
Application Number:	15/137,134
Patent Claims:	1. A method for isolating a preselected polypeptide, the method comprising: expressing a tandem polypeptide in a cell, wherein the tandem polypeptide forms an inclusion body, wherein the tandem polypeptide comprises the preselected polypeptide, an inclusion body fusion partner, and a cleavable peptide linker between the inclusion body fusion partner and the preselected polypeptide, and wherein the inclusion body fusion partner comprises an amino acid sequence of any of SEQ ID NOS: 7-14 or a variant thereof, wherein the variant has 75% or greater sequence homology to at least one of SEQ ID NOS: 7-14 and wherein the variant includes a hydrophobic core consisting of residues 22-29 of SEQ ID NO:130; isolating the inclusion body from the cell; and cleaving the inclusion body isolated from the cell, via the cleavable linker, to cleave the preselected polypeptide from the inclusion body fusion partner. 2. The method of claim 1, wherein the amino acid at residue 23 of SEQ ID NO:130 is threonine. 3. The method of claim 1, wherein the amino acid at residue 28 of SEQ ID NO:130 is lysine. 4. The method of claim 1, wherein the amino acid at residue 23 of SEQ ID NO:130 is threonine and the amino acid at residue 28 of SEQ ID NO:130 is lysine. 5. The expression cassette of claim 1, wherein the cleavable peptide linker can be cleaved by a cleavage agent selected from the group consisting of a palladium, a cyanogen bromide, a Clostripain, a Thrombin, a Trypsin, a Trypsin-like protease, a Carboxypeptidase, an Enterokinase, a Kex 2 protease, an Omp T protease, a Factor Xa protease, a Subtilisin, a HIV protease, a Rhinovirus protease, a Furilisin protease, an IgA protease, a Human Pace protease, a Collagenase, a Plum pos potyvirus, a Poliovirus 2Apro protease, a Poliovirus 3C protease, a Nia protease, a Genenase, a Furin, a Chymotrypsin, an Elastase, a Subtilisin, a Proteinase K, a Pepsin, a Rennin, a microbial aspartic proteases, a Papain, a Ficin, a Bromelain, a Collagenase, a Thermolysin, an Endoprotease Arg-C, an Endoprotease Glu-C, an Endoprotease Lys-C, a Kallikrein and a Plasmin. 6. The method of claim 1, wherein the preselected polypeptide comprises a GLP-1, a GLP-2, a PTH, a GRF, a clostripain, or a variant thereof. 7. The method of claim 1, wherein the preselected polypeptide comprises a GRF or a variant thereof. 8. The method of claim 1, wherein the cell is a prokaryotic cell or a eukaryotic cell. 9. The method of claim 1, wherein the cell is a bacterium. 10. The method of claim 9, wherein the bacterium is Escherichia coli. 11. The method of claim 1, wherein the cell is a yeast cell, an insect cell or a mammalian cell. 12. A method for isolating a preselected polypeptide, the method comprising: expressing a tandem polypeptide in a cell, wherein the tandem polypeptide forms an inclusion body, wherein the tandem polypeptide comprises the preselected polypeptide, an inclusion body fusion partner, and a cleavable peptide linker between the inclusion body fusion partner and the preselected polypeptide, and wherein the inclusion body fusion partner comprises an amino acid sequence of any of SEQ ID NOS: 2-6, 12, or 15 or a variant thereof, wherein the variant has 75% or greater sequence homology to at least one of SEQ ID NOS: 2-6, 12, or 15 and wherein the variant includes a hydrophobic core consisting of the amino acid sequence of SEQ ID NO:92 or the amino acid sequence of SEQ ID NO:92 with a single amino acid substitution therein; isolating the inclusion body from the cell; and cleaving the inclusion body isolated from the cell, via the cleavable linker, to cleave the preselected polypeptide from the inclusion body fusion partner. 13. The method of claim 12, wherein the amino acid substitution is at residue 4 of SEQ ID NO:92. 14. The expression cassette of claim 12, wherein the cleavable peptide linker can be cleaved by a cleavage agent selected from the group consisting of a palladium, a cyanogen bromide, a Clostripain, a Thrombin, a Trypsin, a Trypsin-like protease, a Carboxypeptidase, an Enterokinase, a Kex 2 protease, an Omp T protease, a Factor Xa protease, a Subtilisin, a HIV protease, a Rhinovirus protease, a Furilisin protease, an IgA protease, a Human Pace protease, a Collagenase, a Plum pos potyvirus, a Poliovirus 2Apro protease, a Poliovirus 3C protease, a Nia protease, a Genenase, a Furin, a Chymotrypsin, an Elastase, a Subtilisin, a Proteinase K, a Pepsin, a Rennin, a microbial aspartic proteases, a Papain, a Ficin, a Bromelain, a Collagenase, a Thermolysin, an Endoprotease Arg-C, an Endoprotease Glu-C, an Endoprotease Lys-C, a Kallikrein and a Plasmin. 15. The method of claim 12, wherein the preselected polypeptide comprises a GLP-1, a GLP-2, a PTH, a GRF, a clostripain, or a variant thereof. 16. The method of claim 12, wherein the preselected polypeptide comprises a GRF or a variant thereof. 17. The method of claim 12, wherein the cell is a prokaryotic cell or a eukaryotic cell. 18. The method of claim 12, wherein the cell is a bacterium. 19. The method of claim 18, wherein the bacterium is Escherichia coli. 20. The method of claim 12, wherein the cell is a yeast cell, an insect cell or a mammalian cell.

Details for Patent 9,951,368

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2039-02-26